Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease by unknown
RESEARCH ARTICLE Open Access
Intestinal dysbiosis is common in systemic
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Abstract
Background: Recent evidence suggests a link between autoimmunity and the intestinal microbial composition in
several rheumatic diseases including systemic sclerosis (SSc). The objective of this study was to investigate the
prevalence of intestinal dysbiosis in SSc and to characterise patients suffering from this potentially immunomodulatory
deviation.
Methods: This study consisted of 98 consecutive patients subject to in-hospital care. Stool samples were analysed for
intestinal microbiota composition using a validated genome-based microbiota test (GA-map™ Dysbiosis Test, Genetic
Analysis, Oslo, Norway). Gut microbiota dysbiosis was found present as per this standardised test. Patients were
examined regarding gastrointestinal and extraintestinal manifestations of SSc by clinical, laboratory, and radiological
measures including esophageal cineradiography, the Malnutrition Universal Screening Tool (MUST), levels of plasma
transthyretin (a marker of malnutrition) and faecal (F-) calprotectin (a marker of intestinal inflammation).
Results: A majority (75.5%) of the patients exhibited dysbiosis. Dysbiosis was more severe (rs = 0.31, p = 0.001) and
more common (p = 0.013) in patients with esophageal dysmotility. Dysbiosis was also more pronounced in patients
with abnormal plasma levels of transthyretin (p = 0.045) or micronutrient deficiency (p = 0.009). In 19 patients at risk for
malnutrition according to the MUST, 18 exhibited dysbiosis. Conversely, of the 24 patients with a negative dysbiosis
test, only one was at risk for malnutrition. The mean ± SEM levels of F-calprotectin were 112 ± 14 and 45 ± 8 μg/g in
patients with a positive and negative dysbiosis test, respectively. Dysbiosis was more severe in patients with skin
telangiectasias (p = 0.020), pitting scars (p = 0.023), pulmonary fibrosis (p = 0.009), and elevated serum markers of
inflammation (p < 0.001). However, dysbiosis did not correlate with age, disease duration, disease subtype, or extent of
skin fibrosis.
Conclusions: In this cross-sectional study, intestinal dysbiosis was common in patients with SSc and was associated
with gastrointestinal dysfunction, malnutrition and with some inflammatory, fibrotic and vascular extraintestinal
features of SSc. Further studies are needed to elucidate the potential causal relationship of intestinal microbe-host
interaction in this autoimmune disease.
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Background
Systemic sclerosis (SSc) is an autoimmune systemic dis-
ease of unknown etiology. Genetic factors may only partly
explain the pathobiology, and as yet uncharacterised en-
vironmental factors have been suggested to have a major
influence on the development of SSc [1]. The number of
bacteria in the human gastrointestinal (GI) tract has been
estimated to 1014, reaching a biomass of around 2 kg [2].
In both health and disease, these microbiota are in con-
tinuous interaction with the epithelium and immune cells
of the GI mucosa, and have profound effects on the host’s
local and systemic immune system [3]. Maintenance of a
balanced bidirectional interaction has been suggested to
be essential in preventing development and progression of
autoimmune diseases [4].
Altered microbiota composition, commonly referred
to as dysbiosis, has been shown to induce and modulate
systemic inflammation in animal models of rheumatic
diseases and other immune-mediated inflammatory dis-
eases (IMIDs) [5–7]. In the field of rheumatology, intestinal
dysbiosis has been associated with rheumatoid arthritis
(RA), systemic lupus erythematosus, Sjögren’s syndrome
and ankylosing spondylitis [7–11]. A randomised double-
blind placebo-controlled clinical trial in RA patients
indicated that disease activity may be sensitive to
modulation of gut microbiota through ingestion of
probiotics [12]. In contrast, a similar trial did not
show any significant differences between probiotics
and placebo [13].
In SSc, small intestinal bacterial overgrowth is a well-
described complication associated with GI dysmotility, GI
discomfort, and malnutrition [14, 15]. Successful treat-
ment of small intestinal bacterial overgrowth in SSc leads
to improvement in GI symptoms [14]. Recently, alter-
ations also in the colonic microbial composition in SSc
have been reported [16].
Assessment of GI disease in SSc is challenging. Esopha-
geal cineradiography has been suggested as the gold
standard in the objective assessment of GI SSc [17].
Others and we have suggested that faecal calprotectin
(F-calprotectin) constitutes a feasible tool in the evalu-
ation of GI SSc [15, 18]. Malnutrition is one facet of GI
disease that has been linked not only to morbidity and
decreased quality of life, but also to increased mortality
[19]. The Malnutrition Universal Screening Tool (MUST)
is a validated method for identifying SSc patients at risk
for malnutrition [20]. Decreased plasma levels of trans-
thyretin, also known as prealbumin, represent a biomarker
of malnutrition that also predicts mortality in SSc [19, 21].
The objective of this study was to examine the preva-
lence of dysbiosis in SSc. Furthermore, we aimed at ex-
ploring how intestinal dysbiosis relates to extraintestinal




Consecutive patients fulfilling the American Congress of
Rheumatology/European League Against Rheumatism
(ACR/EULAR) 2013 classification criteria for SSc and
subject to planned in-hospital care due to SSc at the Skane
University Hospital in Lund, Sweden between April 2014
and October 2015, were invited to this study. Out of 226
patients, 100 subjects both agreed to participate and were
able to provide a fresh stool sample during their in-
hospital stay. Patients with inflammatory bowel disease
(IBD), intestinal malignancy, and/or colostomy were ex-
cluded (n = 2). In total, the study cohort consisted of 98
patients.
Ethics
The study was approved by the Regional Ethics Review
Board, Lund, Sweden, reference number 2011/596. In-
formed written consent was obtained from all patients
before study inclusion and the study conformed to the
ethical guidelines of the Declaration of Helsinki.
Clinical assessment
The following data were collected: age, sex, and disease
duration (defined both as years since onset of Raynaud’s
phenomenon [RP] and years since the first non-RP
manifestation). Patients were classified as having either
diffuse cutaneous SSc (dcSSc) or limited cutaneous SSc
(lcSSc) [22]. Esophageal function was assessed by ciner-
adiography and evaluated by a radiologist, as previously
described [23]. The cineradiograms were obtained by
recording the swallowing of barium contrast in upright
and prone positions using a high-speed camera. Esophageal
motility dysfunction was categorised as absent, mild, mod-
erate, or severe. Skin involvement was assessed using the
modified Rodnan skin score (mRSS) [24]. The presence or
absence of skin telangiectasia and pitting scars were noted.
Pulmonary function was evaluated using a body ple-
thysmograph (Erich Jaeger GmbH, Hoechberg, Germany).
Lung fibrosis was identified by high-resolution computed
tomography. Echocardiography was performed on all pa-
tients, and pulmonary arterial hypertension (PAH) was di-
agnosed by means of right heart catheterisation.
Assessment of medical records
Medical records were systematically studied. Height and
weight were noted as well as weight change during the
last 12 months. Individual MUST scores were calculated
as previously described [20]. A MUST score of 0 repre-
sents low risk for malnutrition, a score of 1 medium risk,
and a score of ≥2 high risk. Patients’ usage of prescribed
drugs including proton pump inhibitors (PPIs), antibiotics,
glucocorticoids and immunosuppressive agents were
noted.
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Assessment of intestinal symptoms
All patients were systematically questioned regarding the
following GI symptoms: heartburn (dyspepsia), dyspha-
gia, diarrhea, and/or constipation. These were recorded
as present or not.
Laboratory examinations
Blood tests included measurements of C-reactive protein
(CRP), erythrocyte sedimentation rate (ESR), haptoglobin,
orosomucoid, α1-antitrypsin, immunoglobulin (Ig)G, IgM,
IgA, vitamin B12, folic acid, ferritin, iron, transferrin iron-
binding capacity (TIBC) and transthyretin. Subjects with
an iron/TIBC ratio < 0.16 were considered to be iron
deficient [25]. F-calprotectin was measured using a
commercially available enzyme-linked immunosorbent
assay (ELISA, Calpro, Lysaker, Norway). The lower limit
of the ELISA was 30 μg/g and values below this cutoff
were estimated as 20 μg/g. In accordance with published
data and recommendations from the manufacturer, we
considered F-calprotectin levels < 50 μg/g to be within
normal range [26].
Assessment of gut dysbiosis
The GA-map™ Dysbiosis Test (Genetic Analysis, Oslo,
Norway) has been developed and validated in relation to
a Scandinavian control population to identify dysbiosis
in adults by genetic analysis of a stool sample. The test
makes use of 54 bacterial ribosomal RNA probes specific
for various intestinal bacterial species or clades to generate
genomic data on the intestinal microbiota composition.
Using a defined algorithm, these data are subsequently
translated into a Dysbiosis Index Score ranging from 1 to 5
(grades 1–2 are defined as eubiosis and 3–5 as dysbiosis).
The test has been compared with MiSeq Illumina
sequencing-based protocols and proven successful in
identifying dysbiosis [6, 27]. In a healthy control popu-
lation, 84% exhibited eubiosis and 16% dysbiosis [27].
In the current study, gut microbiota eubiosis and dysbiosis
were delineated as per the standardised GA-map™ Dysbio-
sis Test results.
Statistical analyses
The Mann-Whitney U test was used to compare the
degree of dysbiosis and the χ2 test to compare the fre-
quency of dysbiosis in patients with and without various
manifestations of SSc. Spearman correlation coefficient
(rs) was used to correlate the Dysbiosis Index Score with
other continuous variables.
Results
Study population characteristics and levels of dysbiosis
Systemic sclerosis patients (n = 98) were examined for
an array of characteristics and assessed for intestinal dys-
biosis analysing their stools using the GA-map™ Dysbiosis
Test. Patient characteristics are presented in Table 1. A
majority (75.5%) of the patients exhibited dysbiosis to
some degree (score 3–5), and a significant proportion
(24.9%) suffered from severe dysbiosis (score 5, Fig. 1).
Dysbiosis was associated with gastrointestinal
manifestations of systemic sclerosis
A majority of the patients (84%) exhibited esophageal
dysfunction, and dysbiosis was significantly more com-
mon in this group (p = 0.013; Fig. 2). The degree of dys-
motility correlated with intestinal dysbiosis (Table 2).
Malnutrition was frequent; 53% of the patients exhibited
Table 1 Patient characteristics
n (%)
Systemic sclerosis subtype
limited cutaneous SSc 77 (78)











Pulmonary arterial hypertensiona 13 (13)
Pitting scars, current 23 (23)
Lung fibrosisb 35 (36)
Pathological cineradiography 82 (84)
Regular PPI usage 78 (80)
Immunosuppressive therapy
mycophenolate mofetil 23 (23)
methotrexate 5 (5)
azathioprine 10 (10)
no immunosuppressive therapy 60 (61)
median interquartile range
Modified Rodnan skin score
limited cutaneous 2 (0, 4)
diffuse cutaneous 10 (4, 22)
Disease duration, yearsc 6 (2, 16)
Prednisolone, daily intake (mg) 0 (0, 4)
ANA anti-nuclear antibodies, ACA anti-centrome antibodies, ARA anti-RNA
polymerase III antibodies, ATA anti-topoisomerase1 antibodies, PPI proton
pump inhibitor
aAs determined by right heart catheterisation
bAs determined on high-resolution computed tomography
cYears since first non-Raynaud’s phenomena symptom
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deficiency of folic acid, vitamin B12, and/or iron. Nine-
teen patients had a MUST score of ≥ 1, of which 18 ex-
hibited dysbiosis, and 17 patients had pathological levels
of P-transthyretin of which 15 exhibited dysbiosis. Pa-
tients with these malnutrition-associated characteristics
(any deficiency, MUST ≥ 1, and/or abnormal transthyre-
tin levels) displayed a higher degree of dysbiosis (Fig. 2)
compared to the other subjects. Similarly, patients with
any self-reported GI symptoms (Fig. 2) and patients
using PPIs had a higher degree of dysbiosis compared to
the other subjects (p = 0.019 and p = 0.002, respectively).
Subanalysis of different types of self-reported GI symp-
toms did not reveal any significant associations. A major-
ity of the SSc subjects exhibited abnormal F-calprotectin
levels which were associated with the degree of dysbiosis
(Fig. 2, Table 2). The mean ± SEM levels of F-calprotectin
were 112 ± 14 and 45 ± 8 μg/g in patients with a positive
and negative dysbiosis test, respectively.
Dysbiosis was associated with certain extraintestinal
manifestations of systemic sclerosis
The degree of dysbiosis was analysed in reference to
major fibrotic and vascular extraintestinal manifestations
of SSc. Dysbiosis frequencies and severity did not differ
between patients with dcSSc and lcSSc (Fig. 2), and the
degree of dysbiosis did not correlate with the extent of
skin disease (Table 2). However, dysbiosis was more pro-
nounced among patients with pulmonary fibrosis (Fig. 2).
We were unable to identify any association between the
degree of dysbiosis and vital capacity or carbon monoxide
diffusing capacity, (rs = -0.126, p = 0.216, n = 98; rs = -0.172,
p = 0.232, n = 96). Among the 98 patients, 13 (13.3%) suf-
fered from PAH. Dysbiosis was not more common or more
severe among these (p = 0.316). However, dysbiosis was
more severe among the 39 patients exhibiting skin
telangiectasia, and among the 23 patients with pitting
scars (Fig. 2). Dysbiosis was not more severe or prevalent
among subjects with antibodies against centromere,
topoisomerase 1, or RNA polymerase III. The degree of
dysbiosis did not correlate with usage of glucocorticoids
(rs = 0.15, p = 0.139) and was not associated with usage
of immunosuppressive therapy or antibiotics (p = 0.344
and p = 0.684, respectively).
Dysbiosis was associated with laboratory markers of
inflammation
Routine blood tests addressing systemic inflammation
were assessed and correlated with the degree of dysbio-
sis. The grade of dysbiosis correlated with levels of CRP,
haptoglobin, orosomucoid, and α1-antitrypsin, but not
with the levels of ESR, IgG, IgM or IgA (Table 2). Of
note, all three patients with IgA levels above reference
levels had a Dysbiosis Index Score of 5 (p = 0.059).
Dysbiosis was common also in patients with early
systemic sclerosis
Disease duration was defined by two different measures
and subsequently correlated with the degree of dysbiosis.
The Dysbiosis Index Score did not correlate either with
disease duration defined as years since RP debut or disease
duration defined as years since first non-RP symptom or
age (Table 2). Dysbiosis was prevalent among patients
with less than 2 years since the debut of RP or first non-
RP symptom (73% and 72%, respectively), similarly to pa-
tients with more long-standing disease (76% and 76%,
Fig. 2).
Analysis of specific bacterial genera
In a secondary analysis, we examined the frequency of
specific bacterial genera and species previously associated
with SSc, included in the GA-map™ Dysbiosis Test. A
large proportion of patients with SSc exhibited low levels
of Faecalibacterium prausnitzii (66/98; 67.3%) and/or
Clostridiaceae (25/98; 25.5%) compared to eubiotic indi-
viduals. Also, relatively high levels of Lactobacillus (31/98;
31.6%) but not Bifidobacterium (6/98; 6.1%) were com-
mon among our subjects.
Discussion
In this cross-sectional study encompassing 98 SSc patients
we show that intestinal dysbiosis is common in SSc and is
related to GI manifestations of disease. Also, we show that
dysbiosis is associated with certain extraintestinal SSc fea-
tures of inflammatory, vascular, and fibrotic type. We
present data showing that intestinal dysbiosis is already
present early in the course of SSc, indicating that dysbiosis
may precede initial signs of fibrosis.
Several IMIDs have been associated with alterations in
the microbial composition in the intestine, including
Fig. 1 Dysbiosis is common in patients with systemic sclerosis.A
majority of the study population suffers from dysbiosis, as defined
by the GA-map™ Dysbiosis Test, with 25% exhibiting
pronounced dysbiosis





Fig. 2 Dysbiosis correlates with gastrointestinal and some extraintestinal manifestations of SSc, but not disease subtype or immunosuppressive
therapy. Dysbiosis was prevalent in patients with both short and long disease duration (a), lcSSc and dcSSc (b) as well as in patients with and without
immunosuppressive therapy (c), with no significant differences between groups. Dysbiosis was more pronounced in patients with gastrointestinal
manifestations of SSc including pathological oesophageal function, p = 0.036 (d); at risk for malnutrition, p = 0.005 (e); low levels of P-transthyretin,
p = 0.045 (f); increased levels of F-calprotectin, p < 0.001 (g); gastrointestinal symptoms present, p = 0.019 (h) or micronutrient deficiency p = 0.009
(i). Also, patients with pulmonary fibrosis, p = 0.009 (j); telangiectasias, p = 0.020 (k); or pitting scars, p = 0.023 (l) had more pronounced dysbiosis
compared to other patients. dcSSc diffuse cutaneous SSc, F-calprotectin faecal calprotectin, lcSSc limited cutaneous SSc, MUST Malnutrition
Universal Screening Tool
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RA, systemic lupus erythematosus, Sjögren’s syndrome,
and IBD [7, 8, 11, 28]. Among human IMIDs, dysbiosis
has been most extensively studied in IBD. These patients
display decreased diversity in their gut microbiota, in-
creased numbers of bacteria driving inflammatory activity,
and decreased numbers of bacteria with immunoregula-
tory effects [28]. An important question is whether
IBD-associated dysbiosis is a primary or secondary
phenomenon. In animal models of IBD both loss of im-
munoregulatory and addition of disease-promoting bac-
teria have been shown to contribute to disease activity,
supporting a primary disease-driving role for dysbiosis
[29]. In IBD patients, various strategies for manipulating
the gut microbiota, including exclusive enteral nutrition,
prebiotics, probiotics, postbiotics, and faecal microbiota
transplantation have shown mixed but overall promising
results [30].
Molecular analyses have revealed some similarities be-
tween the process of IBD-associated intestinal fibrosis
and SSc-associated skin fibrosis, including transforming
growth factor beta (TGF-β) and peroxisome proliferator-
activated receptor-dependent pathways resulting in col-
lagen I production by fibrocytes and fibroblasts [31, 32].
Furthermore, while inflammation can be treated by im-
munosuppressive therapy, these fibrotic processes are
resilient also to modern therapy in both diseases. In
IBD as well as SSc, elevated F-calprotectin levels are
common, indicating intestinal inflammation. Similar to
data presented in this study, increased F-calprotectin
levels have been associated with dysbiosis also in IBD [33].
Volkmann et al. recently reported altered microbial
colonic mucosal composition in 17 SSc patients [16].
Our study comprising 98 SSc patients corroborates this
finding, as we show a high incidence of dysbiosis in our
patients. We also report low levels of the immunoregula-
tory bacteria Faecalibacterium prausnitzii, which is in
agreement with studies in IBD [34]. In accordance with
Volkmann et al., we report high levels of Lactobacillus
in SSc patients, which contrasts this disease from several
other IMIDs [4]. As previously suggested, this finding
might raise novel questions regarding the usage of
Lactobacilli-containing probiotics in SSc.
Our report is based on faecal analyses and not analyses
on colonic lavage or intestinal biopsies. Consequently, a
weakness of our approach is the inability to specifically
focus on bacteria prevalent in the interface between the
colonic mucosa and the intestinal lumen. It is note-
worthy that even though different methodologies were
used, our major finding is consistent with Volkmann’s
report.
Objective evaluation of GI disease in SSc is challen-
ging. SSc can affect the GI tract in several different ways
including dysmotility, malnutrition, inflammation, and
fibrosis. In our study, we evaluated the GI tract by assess-
ment of esophagus motility using barium cineradiography
which has previously been suggested as the gold standard
in objective evaluation of this disease [17]. We inves-
tigated malnutrition by laboratory markers including
P-transthyretin, and anthropometric data using the
MUST [19, 20]. While malnutrition in SSc has been
suggested to be caused by malabsorption [35], additional
mechanisms are likely to be involved including cachexia
caused by the chronic inflammatory process [36].
A majority of our patients were prescribed PPI and
usage of this medication was interestingly enough asso-
ciated with dysbiosis. However, previous studies have
failed to show that PPI usage per se causes significant
aberrations in colonic microbiota composition [37]. In
agreement with a previous study and interpretation by
Krause et al. [36], we suggest that regular use of PPI pri-
marily is an unspecific marker of symptomatic GI SSc.
In this study, all patients were questioned about GI
symptoms, and indeed, dysbiosis was more common in
patients with GI symptoms indicating that a validated
questionnaire, such as the UCLA SCTC GIT 2.0 should
be included in future studies [38].
The primary aim of this study was to study the preva-
lence of dysbiosis in SSc. Unlike whole-genome sequencing
studies, we have only limited data on specific bacterial
genera. Furthermore, we do not have data on intestinal
metabolic pathways used by the different microbiomes
Table 2 Correlation between the Dysbiosis Index Score and





Laboratory markers of inflammation
C-reactive protein 98 0.35 <0.001
Haptoglobin 98 0.34 <0.001
Orosomucoid 98 0.39 <0.001
α1-antitrypsin 98 0.27 0.007
Erythrocyte sedimentation rate 98 0.16 0.156
IgA 98 0.13 0.266
IgM 98 −0.05 0.654
IgG 98 −0.05 0.632
Faecal calprotectin 83 0.38 <0.001
Disease characteristics
Years since onset of RP 94 −0.07 0.501
Years since the first non-RP
symptom
89 0.09 0.383
Patient’s age at dysbiosis
analysis
98 0.08 0.413
modified Rodnan skin score 98 0.05 0.659
Dysmotility of oesophagus 97 0.31 0.002
Ig immunoglobulin, RP Raynaud’s phenomenon
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our patients harbor. Further studies encompassing such
analyses are needed to further elucidate the intricate
relationship between the host and the microbiome in
SSc [39].
We can only speculate on the mechanisms behind the
associations between dysbiosis and GI or extraintestinal
manifestations of SSc. It can be hypothesised that several
of these manifestations are indirect markers of severe
disease. However, we were unable to identify an associ-
ation between the mRSS, disease subtype, autoantibody
profile, and immunosuppressive therapy. Taking this into
consideration, we are therefore inclined to suggest that
the relationship between the intestinal microbiome and
SSc is multifactorial and related to factors independent
of disease severity or autoantibody status. We note that
dysbiosis is associated with increased serum levels of
markers of inflammation and we suggest that further
studies are warranted to elucidate the impact of GI dys-
biosis on the immune system in SSc.
Conclusions
Examining a large cross-sectional cohort of SSc patients
we report that intestinal dysbiosis is prevalent in early as
well as late disease, and associated with both GI and extrain-
testinal manifestations of SSc. Given our current knowledge
from other IMIDs, we suggest that an aberration of the in-
testinal microbiota may contribute to the development of
systemic inflammation and fibrosis, although causal relation-
ships remain to be established.
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